Yves Perel

Summary

Affiliation: CHU de Bordeaux
Country: France

Publications

  1. pmc Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study
    Virginie Gandemer
    Department of Pediatric Hematology, University Hospital of Rennes, Rennes, France
    BMC Cancer 9:14. 2009
  2. pmc Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status
    Y Perel
    Laboratory of Differentiation and Development Biology, EA DRED 483, University of Bordeaux 2, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
    Br J Cancer 86:117-22. 2002
  3. ncbi request reprint Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy
    Yves Perel
    Department of Pediatrics, Onco Hematology Unit, University Hospital, 33076 Bordeaux, France
    Pediatrics 109:1170-3. 2002
  4. ncbi request reprint Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant
    Yves Perel
    Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Centres Hospitalo Universitaires de Bordeaux, France
    J Clin Oncol 20:2774-82. 2002
  5. ncbi request reprint Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group
    Y Perel
    Pediatric Onco Hematology Unit, University Hospital, Bordeaux, France
    Leukemia 19:2082-9. 2005
  6. ncbi request reprint [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use]
    Y Perel
    Unité d oncohématologie pédiatrique, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, CHU de Bordeaux, 33076 Bordeaux, France
    Arch Pediatr 11:834-42. 2004
  7. doi request reprint A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age
    Sylvie Monnereau-Laborde
    Department of Pediatric Hemato Oncology, CHU Bordeaux, Children s Hospital, Place Amelie Rabat Leon, Bordeaux, France
    Pediatr Blood Cancer 57:965-71. 2011
  8. ncbi request reprint Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol
    Dominique Valteau-Couanet
    Departement de Pediatrie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 23:532-40. 2005
  9. ncbi request reprint Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology
    Nathalie Aladjidi
    Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Place Amelie Raba Leon, 33076 Bordeaux, France
    J Clin Oncol 21:4377-85. 2003
  10. ncbi request reprint High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification
    Anne Laprie
    Département d Hémato Oncologie, Hopital des Enfants, Toulouse, France
    Cancer 101:1081-9. 2004

Collaborators

Detail Information

Publications21

  1. pmc Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study
    Virginie Gandemer
    Department of Pediatric Hematology, University Hospital of Rennes, Rennes, France
    BMC Cancer 9:14. 2009
    ..Here we report the long-term results of the FRALLE 93 study conducted in the era before the use of tyrosine kinase inhibitors...
  2. pmc Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status
    Y Perel
    Laboratory of Differentiation and Development Biology, EA DRED 483, University of Bordeaux 2, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
    Br J Cancer 86:117-22. 2002
    ..Finally, our results suggest that galanin influences neuroblastoma growth and development as an autocrine/paracrine modulator. These findings suggest potential critical implications for galanin in neuroblastic tumours development...
  3. ncbi request reprint Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy
    Yves Perel
    Department of Pediatrics, Onco Hematology Unit, University Hospital, 33076 Bordeaux, France
    Pediatrics 109:1170-3. 2002
    ..In some cases of Gaucher's disease, alternative strategies such as fractionated or further increased ERT, gene therapy, or glucosyltransferase inhibitor should be explored...
  4. ncbi request reprint Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant
    Yves Perel
    Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Centres Hospitalo Universitaires de Bordeaux, France
    J Clin Oncol 20:2774-82. 2002
    ..To determine whether the use of maintenance therapy (MT) delivered after intensive induction and consolidation therapy confers any advantage in childhood acute myeloid leukemia (AML)...
  5. ncbi request reprint Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group
    Y Perel
    Pediatric Onco Hematology Unit, University Hospital, Bordeaux, France
    Leukemia 19:2082-9. 2005
    ..6+/-8 vs 59+/-8%; P=0.05), while the 5-year DFS was not significantly different. Exposure to low-dose MT might contribute to clinical drug resistance and treatment failure in relapsing patients...
  6. ncbi request reprint [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use]
    Y Perel
    Unité d oncohématologie pédiatrique, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, CHU de Bordeaux, 33076 Bordeaux, France
    Arch Pediatr 11:834-42. 2004
    ..Recent advances in understanding the biology and genetics of neuroblastoma will ultimately allow to select poor-risk patients for appropriate future biologically based therapies...
  7. doi request reprint A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age
    Sylvie Monnereau-Laborde
    Department of Pediatric Hemato Oncology, CHU Bordeaux, Children s Hospital, Place Amelie Rabat Leon, Bordeaux, France
    Pediatr Blood Cancer 57:965-71. 2011
    ..To improve outcome and overall survival (OS) in high-risk neuroblastoma, NB96 induction therapy was intensified using sequential high-dose chemotherapy and autologous stem cell rescue...
  8. ncbi request reprint Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol
    Dominique Valteau-Couanet
    Departement de Pediatrie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 23:532-40. 2005
    ..To test the metastatic response rate in stage 4 neuroblastoma, using dose-intensive induction chemotherapy in a multi-institutional setting...
  9. ncbi request reprint Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology
    Nathalie Aladjidi
    Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Place Amelie Raba Leon, 33076 Bordeaux, France
    J Clin Oncol 21:4377-85. 2003
    ..The goals of this retrospective study were to determine whether these children could be treated successfully with a salvage regimen and to establish the optimal therapeutic strategy...
  10. ncbi request reprint High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification
    Anne Laprie
    Département d Hémato Oncologie, Hopital des Enfants, Toulouse, France
    Cancer 101:1081-9. 2004
    ..The objective of this study was to determine whether systemic and regional, intensified treatment can improve the outcome of children who present with a localized neuroblastoma (NB) with MYCN amplification (MNA)...
  11. doi request reprint Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003
    Julie Tandonnet
    Bordeaux University and Bordeaux University Hospital, Pediatric Oncology and Hematology Unit, 33076 Bordeaux, France
    Pediatr Blood Cancer 54:927-33. 2010
    ..To determine the epidemiology of myeloid leukaemia (ML) in children with Down syndrome (DS) and the efficacy of two approaches, low-dose cytarabine-based regimen (LDC) and standard-dose intensive chemotherapy (SD)...
  12. doi request reprint Ectopic Cushing's syndrome due to an adrenal ganglioneuroma
    Jean Benoit Corcuff
    Department of Nuclear Medicine, CHU Bordeaux, Bordeaux, France
    Horm Res Paediatr 73:405-8. 2010
    ..Cortical cell hyperplasia was observed. Conclusion: Benign and differentiated tumors of the neural crest such as ganglioneuromas may be responsible for CS...
  13. doi request reprint Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study
    Caroline Oudot
    Service d hématologie et oncologie pédiatrique, Hopital Mere Enfant, Limoges, France
    J Clin Oncol 26:1496-503. 2008
    ..To identify prognostic factors and to evaluate the outcome of children with acute lymphoblastic leukemia (ALL) failure after induction therapy...
  14. ncbi request reprint Rituximab therapy for childhood Evans syndrome
    Brigitte Bader-Meunier
    Assistance Publique Hopitaux de Paris, Service d hématologie oncologie pédiatrique, Hopital Robert Debre, Paris, France
    Haematologica 92:1691-4. 2007
    ..4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively...
  15. pmc Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE)
    Nathalie Mallol-Mesnard
    INSERM U754, IFR69, 16 Avenue Paul Vaillant Couturier, F 94807 Villejuif Cedex, France
    Int J Epidemiol 36:110-6. 2007
    ..Elucidating the role of vaccination in the aetiology of childhood acute leukaemia (AL) was therefore included in the objectives of an ongoing national study...
  16. ncbi request reprint Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials
    Nicolas Boissel
    Services d Hématologie Pédiatrique et Adulte, Laboratoire Central d Hématologie, Hopital Saint Louis, France
    J Clin Oncol 21:774-80. 2003
    ..To compare pediatric and adult therapeutic practices in the treatment of acute lymphoblastic leukemia (ALL) in adolescents...
  17. doi request reprint Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome
    Paola Ballerini
    Laboratoire d Hematologie, Hopital A Trousseau, INSERM E0210
    Haematologica 93:1658-65. 2008
    ..Likewise, the frequency and the prognostic significance in pediatric T-cell acute lymphoblastic leukemia of the newly characterized NUP214-ABL1 fusion transcript is not yet clear...
  18. ncbi request reprint An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children
    David Nadal
    Division of Infectious Diseases, University Children s Hospital of Zurich, CH 8032 Zurich, Switzerland
    J Infect Dis 186:S123-30. 2002
    ..In general, adverse events were not attributable to valacyclovir and were consistent with disease-related expectations and concomitant therapies. Dosage options for using valacyclovir in children are discussed...
  19. ncbi request reprint Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma
    Maud Monsaingeon
    Service de Medecine Nucleaire, Hopital Haut Leveque, 33604 Pessac, France
    Eur J Pediatr 162:397-402. 2003
    ..Plotting individual levels (normetanephrine versus vanillylmandelic acid or homovanillic acid) allowed a rapid visual analysis that would have missed only one small low grade non-secreting tumour...
  20. ncbi request reprint Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia
    Jean Delorme
    Department of Pharmacy, Research Unit INSERM No 379, France
    J Pediatr Hematol Oncol 25:441-7. 2003
    ..The aim of the current study was to perform an economic evaluation in the same cohort...
  21. ncbi request reprint A 22-year French experience with solid tumors in children with Down syndrome
    Daniel Satgé
    Laboratoire d Anatomie Pathologique, Centre Hospitalier, Tulle, France
    Pediatr Hematol Oncol 20:517-29. 2003
    ..The treatment of solid tumors in DS is difficult, due to physical and psychological impairments, different pharmacogenetic profile, and associated malformations...